Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines

BMC Cancer

Table 6 Comparison between the current study findings and the results of prior studies of sunitinib resistance and cross resistance

Publication year	2013 [2]	2015 [9]	This study		This study
Cell line	ACHN	786-O	SNU-228		SNU-267
Age	22	58	51		43
Sex	male	male	male		male
Ethnicity	Caucasian	Caucasian	Korean		Korean
Origin	metastasized tumor	primary tumor	primary tumor		primary tumor
Cytology	adenocarcinoma	clear cell adenocarcinoma	clear cell adenocarcinoma		clear cell adenocarcinoma
Drug exposure method	continuous	continuous	pulse		pulse
Drug concentration	up to 10 μM	5 μM	3 μM		5.5 to 7 μM
Resistance indicator	IC₅₀	IC₅₀	GR₁₀₀	Efficacy	GR₁₀₀	Efficacy
Fold increase
Sunitinib	5	3.1	3.16	0.82	1.70	0.89
Axitinib			3.47	0.74	1.40	0.89
Erlotinib		4.5
Lapatinib		1.4
Pazopanib		1.6	1.79	0.85	1.16	0.89
Sorafenib	6	1.2	1.10	0.88	1.15	0.91
Everolimus	1	23	0.91	0.86	1.35	0.92
Temsirolimus	1		0.91	0.84	1.07	0.91

ISSN: 1471-2407